Clinically, NSCLC patients with high intratumoral CD45+Rab37+IL-6+ or IL-6+CD163+CD8+PD-1+ immunoreactivity or an increase in plasma IL-6 level are found to be significantly associated with poor prognosis or therapeutic resistance. Here, PTPRC is linked to non-small cell lung carcinoma.